Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.

Medical oncology (Northwood, London, England) - 15 May 2022

Voutsadakis Ioannis A

Abstract excerpt

Colorectal cancer remains a major cause of cancer-related morbidity and mortality. Metastatic disease is still incurable in most cases. New therapies based on a better understanding of the pathogenesis are needed to improve outcomes. Mutations in the catalytic sub-unit of kinase PI3K encoded by gene PIK3CA are common in colorectal cancer cell lines and patient samples. The characteristics of colorectal cancer...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Class I Phosphatidylinositol 3-Kinases
Share to Colorectal Neoplasms
Share to Drug Discovery

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Microsatellite Instability

Share to Phosphatidylinositol 3-Kinases

Share to Phosphoinositide-3 Kinase Inhibitors

Share to Proto-Oncogene Proteins B-raf

Share to Proto-Oncogene Proteins p21(ras)

Source

Identifiers

PMID: 35568775
DOI: 10.1007/s12032-022-01695-y

Genes

PIK3CA
BRAF
KRAS

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Cell line models for drug discovery in PIK3CA-mutated colorectal cancers.PMID 35568775Read ↗

Sensitivities and Dependencies of BRAF Mutant Colorectal Cancer Cell Lines with or without PIK3CA Mutations for Discovery of Vulnerabilities with Therapeutic Potential.Semantic proximity Read ↗

The Landscape of PIK3CA Mutations in Colorectal Cancer.Semantic proximity Read ↗

KRAS mutated colorectal cancers with or without PIK3CA mutations: Clinical and molecular profiles inform current and future therapeutics.Semantic proximity Read ↗

The role of PIK3CA gene mutations in colorectal cancer and the selection of treatment strategiesSemantic proximity Read ↗

Common gene mutations in 103 authenticated colorectal cancer cell linesSemantic proximity Read ↗

Establishment and characterization of 18 human colorectal cancer cell lines.Semantic proximity Read ↗

Molecular characteristics of advanced colorectal cancer and multi-hit PIK3CA mutations.Semantic proximity Read ↗

From PIK3CA Mutations to Rational PI3K Inhibition for the Treatment of Colorectal Cancer.Semantic proximity Read ↗

Pre-clinical use of isogenic cell lines and tumours in vitro and in vivo for predictive biomarker discovery; impact of KRAS and PI3KCA mutation status on MEK inhibitor activity is model dependent.Semantic proximity Read ↗

PIK3CA Mutated Colorectal Cancers Without KRAS, NRAS and BRAF Mutations Possess Common and Potentially Targetable Mutations in Epigenetic Modifiers and DNA Damage Response Genes.Semantic proximity Read ↗

Target-based therapeutic matching in early-phase clinical trials in patients with advanced colorectal cancer and PIK3CA mutations.Semantic proximity Read ↗

Cell Line Models of Molecular Subtypes of Colorectal Cancer.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.